Fulgent Genetics Stock Investor Sentiment

FLGT Stock  USD 18.85  0.10  0.53%   
Slightly above 67% of Fulgent Genetics' investor base is looking to short. The analysis of overall sentiment of trading Fulgent Genetics stock suggests that many investors are alarmed at this time. Fulgent Genetics' investing sentiment can be driven by a variety of factors including economic data, Fulgent Genetics' earnings reports, geopolitical events, and overall market trends.
  

Fulgent Genetics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Fulgent Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Fulgent Genetics Maximum Pain Price Across January 17th 2025 Option Contracts

Fulgent Genetics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Fulgent Genetics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Fulgent Genetics' options.
over a year ago at insidermonkey.com         
Fulgent Genetics, Inc. Q1 2023 Earnings Call Transcript
insidermonkey News
over a year ago at simplywall.st         
Analysts Have Been Trimming Their Fulgent Genetics, Inc. Price Target After Its Latest Report
Simply Wall St News at Macroaxis
over a year ago at zacks.com         
Is Fulgent Genetics Stock Outpacing Its Medical Peers This Year?
zacks News
over a year ago at thelincolnianonline.com         
Fulgent Genetics PT Raised to 37.00 at Piper Sandler
news
over a year ago at investing.com         
Payment of 6198 shares by Jian Xie of Fulgent Genetics subject to Rule 16b-3
Investing News at Macroaxis
over a year ago at zacks.com         
Fulgent Genetics, Inc. Reports Q1 Loss, Tops Revenue Estimates
zacks News
over a year ago at businesswire.com         
Fulgent Reports First Quarter 2023 Financial Results
businesswire News
over a year ago at investing.com         
Fulgent Genetics earnings beat by 0.30, revenue topped estimates
Investing News at Macroaxis
over a year ago at www.macroaxis.com         
Payment of 775 shares by Jian Xie of Fulgent Genetics subject to Rule 16b-3
Macroaxis News
over a year ago at news.google.com         
Comerica Bank Decreases Stake in Fulgent Genetics, Inc. NASDAQ ... - MarketBeat
Google News at Macroaxis
over a year ago at news.google.com         
Nimble companies capitalise on last-mover advantage - Financial Times
Google News at Macroaxis
over a year ago at businesswire.com         
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
businesswire News
over a year ago at simplywall.st         
Fulgent Genetics Is Looking To Continue Growing Its Returns On Capital
Simply Wall St News at Macroaxis
over a year ago at finance.yahoo.com         
Returns Are Gaining Momentum At Fulgent Genetics
Yahoo News
over a year ago at zacks.com         
Are Medical Stocks Lagging Fulgent Genetics This Year?
zacks News
Far too much social signal, news, headlines, and media speculation about Fulgent Genetics that are available to investors today. That information is available publicly through Fulgent media outlets and privately through word of mouth or via Fulgent internal channels. However, regardless of the origin, that massive amount of Fulgent data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Fulgent Genetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Fulgent Genetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Fulgent Genetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Fulgent Genetics alpha.

Fulgent Genetics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Acquisition by Gao Hanlin of 27 shares of Fulgent Genetics subject to Rule 16b-3
10/14/2024
2
Disposition of 4345 shares by Jian Xie of Fulgent Genetics at 19.42 subject to Rule 16b-3
10/25/2024
3
Disposition of tradable shares by Gao Hanlin of Fulgent Genetics at 20.27 subject to Rule 16b-3
10/30/2024
4
Fulgent Genetics Q3 2024 Earnings Preview
11/07/2024
5
Fulgent Genetics Reaches New 1-Year Low Heres What Happened
11/13/2024
6
Fulgent Genetics, Inc. Among the Best Genomics Stocks to Buy Right Now
11/20/2024
7
All You Need to Know About Fulgent Genetics Rating Upgrade to Strong Buy
11/22/2024
8
Disposition of 689 shares by Jian Xie of Fulgent Genetics at 18.2593 subject to Rule 16b-3
11/25/2024
9
Disposition of 1553 shares by Paul Kim of Fulgent Genetics at 18.3 subject to Rule 16b-3
11/29/2024
10
Disposition of 1373 shares by Gao Hanlin of Fulgent Genetics at 19.4999 subject to Rule 16b-3
12/03/2024
11
Possible Bearish Signals With Fulgent Genetics Insiders Disposing Stock
12/04/2024
12
Wall Street Analysts Predict a 31.06 percent Upside in Fulgent Genetics Heres What You Should Know
12/09/2024
13
Acquisition by Jian Xie of 27 shares of Fulgent Genetics subject to Rule 16b-3
12/10/2024
14
Fulgent Genetics, Inc. Short Interest Update - MarketBeat
12/31/2024

Additional Tools for Fulgent Stock Analysis

When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.